Conformal Prediction Enhances Drug Discovery AI Reliability.

Drug discovery and development is a notoriously expensive and failure-prone process, with a major bottleneck being the accurate prediction of molecular properties like solubility, potency, and toxicity. While Artificial Intelligence (AI) has shown promise in accelerating this, its reliability is often compromised by "distribution shift," where experimental conditions diverge from the data used for training. Furthermore, traditional AI models typically provide only single-value point predictions, offering limited guidance for high-stakes experimental design. To address these critical challenges, a new conformal prediction framework has been developed, specifically tailored for scenarios involving label shift. This method generates statistically rigorous prediction intervals by weighting conformal scores based on marginal label probability ratios, crucially without requiring model retraining. This innovation ensures robust uncertainty quantification even when property distributions change, directly tackling a pervasive obstacle to real-world AI application in drug development. By moving beyond mere accuracy to provide actionable confidence measures, this approach significantly enhances the trustworthiness of AI-driven predictions, aligning better with regulatory demands for transparency and uncertainty reporting in billion-dollar development pipelines.